A Phase 3 interventional study of Ranibizumab 0.5 mg/0.05 ml in Macular Edema and Central Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 78 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 11th largest by enrollment, is one of 8 that started in 2012, is one of 25 in phase 3, and was the 38th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 357 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 10th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2012, is one of 22 in phase 3, and was the 14th registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The present study provided additional efficacy and safety data for 0.5-mg ranibizumab using as needed (PRN) dosing over 24 months in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion (CRVO). Spectral domain high-definition optical coherence tomography (OCT) images was analyzed to gain insights into predictive factors for disease progression and the possibility of reduced monitoring was assessed in Year 2. The results of this open-label study provided long-term safety and efficacy data to further guide recommendations on the use of ranibizumab in this indication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
Drug: Ranibizumab 0.5 mg/0.05 ml
Drug page: Ranibizumab
Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
Time frame: Baseline to month 12
Mean Change in Best Corrected Visual Acuity (BCVA) at Month 24 Compared to Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
Time frame: Baseline to Month 24
Mean Average Change in Best Corrected Visual Acuity (BCVA From Baseline Month 12 and Month 24
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 12 (or Month 24). Then, mean average change is calculated as the average of average changes across all patients.
Time frame: Baseline and Month 1 to 12 or Month 24
Mean Average Change in BCVA From First Treatment Interruption (Due to BCVA Stabilization) to Month 12 and Month 24
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Stability in visual acuity after treatment interruption indicates longer duration of the drug efficacy
Time frame: Month 12 and Month 24
Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12 and Month 24 in the Study Eye
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at month 12 as compared with baseline
Time frame: Month 12 and Month 24
Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12 and Month 24
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 and month 24 indicates a positive outcome.
Time frame: Month 12 and Month 24
Mean Change in Central Reading Center (CRC)-Assessed Central Subfield Thickness (CSFT) From Month 12 and Month 24 Compared to Baseline
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation
Time frame: Baseline, Month 12 and Month 24
Mean Change in Patient-reported Outcomes in NEI-VFQ-25 Composite and Subscale Scores at Month 12 and Month 24 Compared to Baseline
The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranges from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also range from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome. Scores per visit and of the change descriptively by visit.
Time frame: Month 12 and Month 24
| Milestone | Ranibizumab Arm |
|---|---|
| Started | 357 |
| Completed | 307 |
| Not completed | 50 |
| Withdrew: Physician decision | 8 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Death | 5 |
| Withdrew: Lost to follow-up | 8 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Adverse event | 12 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
| Letters | Ranibizumab Arm |
|---|---|
| Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline | 12.3 ± 16.72 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement
| Letters | Ranibizumab Arm |
|---|---|
| Mean Change in Best Corrected Visual Acuity (BCVA) at Month 24 Compared to Baseline | 12.1 ± 18.60 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Mean Average Change: for each patient, first average change is calculated as the average of the changes from baseline to Month 1 over Month 12 (or Month 24). Then, mean average change is calculated as the average of average changes across all patients.
| letters | Ranibizumab Arm |
|---|---|
| Month 12 | 11.8 ± 12.44 |
| Month 24 | 12.1 ± 14.20 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. Stability in visual acuity after treatment interruption indicates longer duration of the drug efficacy
| Letters | Ranibizumab Arm |
|---|---|
| Month 12 (n=310) | -2.7 ± 8.04 |
| Month 24 (n=331) | -2.5 ± 8.95 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at month 12 as compared with baseline
| Letters | Ranibizumab Arm |
|---|---|
| BCVA improvement of >= 1 (Month 12) | 296 |
| BCVA improvement of >= 5 (Month 12) | 275 |
| BCVA improvement of >= 10 (Month 12) | 227 |
| BCVA improvement of >= 15 (Month 12) | 175 |
| BCVA improvement of >= 30 (Month 12) | 32 |
| BCVA improvement of >= 1 (Month 24) | 290 |
| BCVA improvement of >= 5 (Month 24) | 265 |
| BCVA improvement of >= 10 (Month 24) | 224 |
| BCVA improvement of >= 15 (Month 24) | 175 |
| BCVA improvement of >= 30 (Month 24) | 44 |
Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at month 12 and month 24 indicates a positive outcome.
| Letters | Ranibizumab Arm |
|---|---|
| Month 12 | 169 |
| Month 24 | 161 |
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation
| Microns | Ranibizumab Arm |
|---|---|
| Change from Baseline at Month 12 | -335.7 ± 285.02 |
| Change from Baseline at Month 24 | -349.1 ± 275.35 |
The survey consists of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranges from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also range from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome. Scores per visit and of the change descriptively by visit.
| Score on a scale | Ranibizumab Arm |
|---|---|
| Change from baseline at Month 12 | 6.9 ± 12.65 |
| Change from baseline at Month 24 | 6.6 ± 14.03 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5mg | — | 64/357 (17.9%) | 244/357 (68.3%) |
| Event | Ranibizumab 0.5mg |
|---|---|
| Atrial fibrillationCardiac disorders | 3/357 |
| Cardiac failureCardiac disorders | 3/357 |
| Cardiac failure congestiveCardiac disorders | 3/357 |
| Myocardial infarctionCardiac disorders | 3/357 |
| Lower respiratory tract infectionInfections and infestations | 3/357 |
| PneumoniaInfections and infestations | 3/357 |
| Glaucoma (Study eye)Eye disorders | 2/357 |
| Retinal ischaemia (Study eye)Eye disorders | 2/357 |
| Visual acuity reduced (Study eye)Eye disorders | 2/357 |
| Pancreatitis acuteGastrointestinal disorders | 2/357 |
| Event | Ranibizumab 0.5mg |
|---|---|
| Intraocular pressure increased (Study eye)Investigations | 43/357 |
| HypertensionVascular disorders | 40/357 |
| NasopharyngitisInfections and infestations | 39/357 |
| Ocular hypertension (Study eye)Eye disorders | 26/357 |
| Eye pain (Study eye)Eye disorders | 25/357 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 24/357 |
| Dry eye (Study eye)Eye disorders | 22/357 |
| Visual acuity reduced (Study eye)Eye disorders | 21/357 |
| HeadacheNervous system disorders | 21/357 |
| Dry eye (Fellow untreated eye)Eye disorders | 19/357 |
| Age, Continuous(Years) | Ranibizumab Arm |
|---|---|
| Mean | 65.5 ± 12.68 |
| Sex: Female, Male(Participants) | Ranibizumab Arm |
|---|---|
| Female | 128 |
| Male | 229 |
The record gives a start of Feb 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab